A comprehensive view of Novartis AG. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Health Canada approves Novartis’ Tabrecta capmatinib tablets to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer; NSCLC is most common type of lung cancer, will affect 30,000 Canadians in 2022

Novartis seeks to grow contract development, manufacturing unit with 15 biotech, cell, gene facilities in US, Europe, Asia; CDMO unit offers microbial fermentation, container filling, global packaging logistics, viral vector production, other services

Novartis reports combination of Kisqali ribociclib and fulvestrant offer survival benefit of almost 16 months in previously untreated breast cancer versus fulvestrant alone; Kisqali is approved in more than 95 countries to treat breast cancer

Novartis Q1 net profit up 8% from a year ago to US$2.2B, sales up 1% year-over-year to US$12.5B with price erosion, generic competition affecting growth; in-market key growth brands Cosentyx, Entresto, Zolgensma, Kisqali deliver solid growth

Sandoz introduces generic version of AbbVie’s Combigan combination eye drop to treat glaucoma in US in three dosing strengths; Combigan is most-used eye pressure medication, with US sales totaling US$373M in 2021

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count